FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to compounds of formula 
(I), 
(III) and 
(VI), possessing properties of TNF-α inhibitors, and their pharmaceutical salts and stereoisomers, as well as to a based on them pharmaceutical composition and a method of treatment with their application. In the general formulae (I), (II), (III) and (VI) X stands for C=O or CH2; R1 stands for -Y-R3; R2 stands for H or (C1-C6)alkyl; Y stands for a 6-10-membered aryl, heteroaryl or heterocycle, each of which can be substituted with one or more halogens; R3 stands for -(CH2)n-aryl, -O-(CH2)n-aryl or -(CH2)n-O-aryl, in which the aryl can be substituted with one or more of the following substituents: (C1-C6)alkyl, which itself can be substituted with one or more halogens; (C1-C6)alkoxy, which itself is substituted with one or more halogens; oxo; amino; carboxyl; cyano; hydroxyl; halogen; deuterium; 6-10-membered aryl or heteroaryl, in case of necessity substituted with one or more (C1-C6)alkyls, (C1-C6)alkoxy or halogens; -CONH2; or -COO-(C1-C6)alkyl, where the alkyl can be substituted with one or more halogens; -(CH2)n-heterocycle; -O-(CH2)n-heterocycle or -(CH2)n-O-heterocycle, where the heterocycle can be substituted with one or more of the following substituents: (C1-C6)alkyl, itself in case of necessity substituted with one or more halogens; (C1-C6)alkoxy, itself substituted with one or more halogens; oxo; amino; carboxyl; cyano; hydroxyl, halogen; deuterium; 6-10-membered aryl or heteroaryl, in case of necessity substituted with one or more (C1-C6)alkyls, (C1-C6)alkoxy or halogens; -CONH2; or -COO-(C1-C6)alkyl, where the alkyl can be substituted with one or more halogens; or -(CH2)n-heteroaryl, -O-(CH2)n-heteroaryl or -(CH2)n-O-heteroaryl, where the heteroaryl can be substituted with one or more of the following substituents: (C1-C6)alkyl, itself in case of necessity substituted with one or more halogens; (C1-C6)alkoxy, itself substituted with one or more halogens; oxo; amino; carboxyl; cyano; hydroxyl; halogen; deuterium; 6-10-membered aryl or heteroaryl, in case of necessity substituted with one or more (C1-C6)alkyls, (C1-C6)alkoxy or halogens; -CONH2; or -COO-(C1-C6)alkyl, where the alkyl can be substituted with one or more halogens; and n=0, 1, 2 or 3.
EFFECT: obtaining the compounds, possessing the properties of the TNF-α inhibitor.
18 cl, 1 tbl, 309 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ISOINDOLINE COMPOUNDS USED FOR TREATING CANCER | 2009 |
|
RU2527952C2 |
| 6-, 7- OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS CONTAINING THEM AND METHODS OF USING THEM | 2008 |
|
RU2476432C2 |
| IMIDES AS TNF-ALPHA INHIBITORS | 1994 |
|
RU2174516C2 |
| 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | 2007 |
|
RU2448101C2 |
| DERIVATIVES OF 5-SUBSTITUTED QUINAZOLINONE, COMPOSITIONS CONTAINING THEM AND METHODS OF APPLICATION THEREOF | 2012 |
|
RU2617989C2 |
| 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND METHODS FOR USING THEM | 2007 |
|
RU2463298C2 |
| DERIVATIVES OF 2-(2,6-DIOXOPIPERIDINE-3-YL)ISOINDOLINE, THEIR SYNTHESIS AND APPLICATION AS INHIBITORS OF INFLAMMATORY CYTOKINES | 1999 |
|
RU2200159C2 |
| CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DESTRUCTION OF ANDROGEN RECEPTORS AND USE THEREOF | 2020 |
|
RU2825000C2 |
| ISOINDOLINONE INHIBITORS OF MDM2-P53 INTERACTION WITH ANTI-CANCER ACTIVITY | 2016 |
|
RU2794333C1 |
| ISOINDOLINE COMPOUND, PRODUCTION METHOD, PHARMACEUTICAL COMPOSITION AND THEIR USE | 2019 |
|
RU2813232C2 |
